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Hypertension affects approximately 1 billion adults worldwide and is a significant risk factor for coronary events, stroke, heart failure, and end-stage kidney disease. 1, 2 Patients with chronic kidney disease (CKD) are at a higher risk of cardiovascular disease, and hypertension is a major factor that increases this risk. 3, 4 Underlying usual blood pressure (defined as the long-term average blood pressure over a period) is of primary importance in the pathophysiology of vascular disease and is the basis for recommendations on optimal blood pressure targets. 5, 6 While underlying usual blood pressure is clearly important, visit-to-visit blood pressure variability has been shown to be an independent predictor of poor cardiovascular outcomes, with higher variability being associated with worse outcomes. 7, 8 The Systolic Blood Pressure Intervention Trial (SPRINT) randomized nondiabetic hypertensives to target systolic blood pressures (SBPs) of 140 mm Hg (standard) or 120 mm Hg (intensive). SPRINT specifically targeted chronic kidney subjects as a prespecified subgroup for recruitment and analysis in the trial. 9 While the SPRINT trial demonstrated fewer cardiovascular events in the intensively treated patients, the relationship between blood pressure variability and aggressive SBP lowering remains unexplored in the CKD cohort.
Targeting lower SBPs may worsen blood pressure variability and this may increase the risk of adverse events related to hypotension such as acute kidney injury (AKI), syncope and falls, as seen in recent clinical trials. [9] [10] [11] At this time, the optimal strategy to balance the benefits of intensive SBP control with the risks of hypoperfusion-related major adverse events is uncertain.
We analyzed data from those SPRINT patients with CKD to investigate if SBP and/or diastolic blood pressure (DBP) variability could predict major adverse cardiovascular events independent of assigned treatment (standard or intensive) and mean blood pressure. We also evaluated in SPRINT patients with underlying CKD, the association of blood pressure variability with adverse events related to blood pressure treatment in SPRINT: hypotension, syncope, and AKI.
METHODS
The SPRINT design and rationale and main results have appeared in prior publications. 9 Briefly, the trial randomized nondiabetic hypertensive patients at least 50 years old with an increased risk of cardiovascular disease (based on a history of clinical or subclinical cardiovascular disease, CKD (with estimated glomerular filtration rate of 29-59 ml/ min/1.73 m 2 ), a 10-year Framingham general cardiovascular disease risk ≥15%, or age ≥75 years), and with SBPs between 130 and 180 mm Hg, to either standard (systolic target 135 to 139) or intensive (systolic target <120) treatment with all major classes of antihypertensive agents. Clinic visits were scheduled at baseline and at months, 1, 2, 3, and then every 3 months thereafter, up to 6 years. Although 3 measurements of blood pressure occurred at each visit, data-forms captured only the average systolic and average diastolic for the 3 measurements. Structured interviews collected self-reported cardiovascular events every 3 months. The primary composite outcome encompassed myocardial infarction, acute coronary syndrome without infarction, stroke, acute decompensated heart failure, and death from cardiovascular causes. The data and safety monitoring board halted the study after 4 years and 9 months (median follow-up 3.26 years) based on positive results that twice exceeded pre-set stopping boundaries.
SPRINT was sponsored by the National Heart, Lung and Blood Institute (NHLBI), the National Institute of Ageing (NIA), the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), and the National Institute of Neurological Disorders and Stroke (NINDS). Access to deidentified data from SPRINT was obtained from the NHLBI following local internal review board approval.
The current analyses focused on the variability of blood pressure in patients with CKD who achieved the target blood pressure for their assigned group. For each subject, the first recorded SBP <140 mm Hg for the standard group, or <120 mm Hg for the intensive group, defined that subject's landmark date. All blood pressure measurements beginning with each subject's landmark date, and none prior to it (leftcensoring), constituted the set of measurements for analyses. The analysis set excluded subjects with no subsequent measurements, subjects who never achieved their assigned target SBP, and those with no blood pressure measurements recorded.
For each subject, the coefficients of variation (CV) for systolic, diastolic, and pulse pressures characterized their respective variabilities. CV measures variability better than SD: the latter correlates with absolute blood pressure; the former normalizes for it. For each CV metric, the unequal variance Student's t-test compared treatment arms. For predictive model use, the analyses also calculated, for each subject, the mean of DBP values and the mean of pulse pressures in the analyses set. Since the models also used treatment group as a predictor, mean SBP would constitute a redundant explanatory variable, and so was not calculated.
Cox proportional hazards regression, using sites as strata, identified independent predictors of the SPRINT primary outcome and of the 3 noted adverse events: hypotension, syncope, and AKI (based on diagnoses coded in hospital discharge summaries and serum creatinine monitoring). Separate regressions by treatment arm used 5 predictors: the CVs of systolic, diastolic, and pulse pressure, and the means of DBP and pulse pressure. Overall regressions used treatment arm as the sixth predictor in addition to the 5 mentioned above. Each regression required univariate P <0.15 to enter the model, and P <0.05 to remain in it. SAS version 9.00 (Cary, NC) and Stata version 13.0 (College Town, TX) facilitated the analyses.
RESULTS
The CKD cohort in SPRINT had 2,646 participants, of whom 2,488 participants (1,273 standard; 1,124 intensive) met analysis inclusion criteria. Table 1 compares the demographic and clinical characteristics between the groups. Study subjects had a variable number of visits depending on their enrollment date relative to the early termination date of the study. The number of BPs following the baseline measurement in the current substudy varied from as few as 2 to as many as 21. Overall in the cohort, the median number of visits was 14 (interquartile range .
These 2,488 subjects sustained 210 primary events (119 standard; 91 intensive). Intensive group subjects maintained a lower hazard for primary events, with hazard ratio (HR) 0.58 (P = 0.0004). CV for DBP independently predicted a greater hazard for the primary outcome, HR 1.126 (P < 0.0001). Separate analyses for standard and intensive treatment subjects each identified CV of DBP as an independent predictor of primary events, with respective HRs 1.107 (P < 0.0001) and 1.100 (P = 0.0004) ( Table 2) .
In analyzing the influence of blood pressure variability on treatment-related adverse events, we found that the intensive group sustained 46 hypotensive, 38 syncopal, and 101 events of AKI. The standard group had 33, 30, and 74 events, respectively. DBP CV independently predicted a greater hazard for syncope, hypotension, and AKI with HRs 1.111, 1.104, and 1.117, respectively (P < 0.001 for each). For each of these outcomes, Figure 1 presents the Kaplan-Meier curves for the entire cohort divided into quartiles based on each patient's diastolic pressure CV, with the first quartile having the smallest CVs and the fourth having the largest.
DISCUSSION
SPRINT showed that lowering SBP to a target goal of less than 120 mm Hg as compared to the standard goal of less than 140 mm Hg, resulted in significantly lower rates of fatal and nonfatal cardiovascular events and death from any cause. 9 However, the intensively treated group had significantly higher incidences of treatment-related serious adverse events including syncope, hypotension, and AKI.
Previous retrospective studies have reported that visitto-visit blood pressure variability increases the risks of cardiovascular events in the CKD population. 12, 13 In a retrospective study in a community-based cohort of 114,900 adults with stages 3 and 4 CKD, blood pressure variability predicted mortality and hemorrhagic stroke (with HRs 1.22 and 1.91, respectively), but was inconsistently associated with heart failure and not significantly associated with acute coronary syndrome and ischemic stroke. 12 A smaller observational study in a cohort of 374 elderly CKD patients showed a significant association between SBP variability and mortality with a HR of 1.05 for all-cause mortality for each 1% increase in SBP variability. 13 A recent metaanalysis estimated that blood pressure variability increased the risk of cardiovascular mortality by 18%, after adjusting for mean blood pressure. 8 Most of the data on blood pressure variability are based on retrospective data or post-hoc analyses of clinical trials in hypertension, none of which include the effects of intensive blood pressure targeted therapy.
The current post-hoc analysis of the prospective SPRINT trial provides new insights to CKD treatment by assessing the effects of large fluctuations in blood pressure accompanying treatment of hypertension on important outcomes. Potential mechanisms for increased BP variability include arterial stiffness and chronic inflammation which are highly prevalent in patients with CKD. 14, 15 Another possible mechanism is high sympathetic activity, also commonly seen in patients with CKD and associated with poor cardiovascular outcomes. 16 Prior studies looking at the predictive value of visit-tovisit blood pressure variability have focused on cardiovascular outcomes and death. Since intensive blood pressure Entries are mean ± SD or percentage. Abbreviations: BMI, body mass index; BP, blood pressure; DBP diastolic BP; eGFR estimated glomerular filtration rate; N number; PP pulse pressure; SBP systolic BP.
a Entries summarize the mean values of all blood pressures beginning with the visit at which the target systolic blood pressure (<140 or <120) was achieved and ending with the last recorded blood pressure. Each entry is the summary statistic, as mean ± SD, across the patients in the cohort designated by the column heading, for the value for each patient across his/her measured blood pressures of the statistic listed in the first column. Abbreviations: CV, coefficients of variation; DBP, diastolic blood pressure; SBP, systolic blood pressure; PP, pulse pressure.
lowering in SPRINT resulted in more hypoperfusive adverse events, we analyzed the association between blood pressure variability and hypotension, syncope, and AKI, in this cohort. We found that increased DBP variability predicted these adverse events, as outlined in the results section. The pathophysiologic links between blood pressure variability and hypoperfusive events are poorly understood. Greater blood pressure variability may produce vascular damage because of the inability of certain vascular beds (for example, cerebrovascular) to maintain auto regulation over wider ranges of blood pressure beyond a point, contributing to adverse events. 17 Patients with CKD have lesser ability to autoregulate renal blood flow, which may increase the risk of hypoperfusive renal injury with higher degrees of blood pressure variability. 18 Our findings highlight the association between blood pressure variability and poor cardiovascular outcomes and adverse events in patients with CKD enrolled in SPRINT. It remains uncertain how clinicians might go about minimizing blood pressure variability while achieving an intensive SBP target in patients with CKD. While our findings are hypothesis generating, a new clinical trial faces challenging design considerations in randomizing subjects to less versus more blood pressure variability. Different antihypertensive treatments appear to have differing effects on blood pressure variability. Limited data suggest that calcium channel blockers and higher doses of nonloop diuretics may be associated with less BP variability. 19 The present study has certain limitations. Firstly, this is a post-hoc analysis of a prospective study and, as such, any inferences garnered are hypothesis generating and may not imply causation. As DBP variation is not subject to direct manipulation, testing the hypothesis prospectively will require indirect methods. Secondly, elimination from the analysis of patients who did not achieve target SBP might bias the results so that a subsequent prospectively studied cohort, which would retain such patients for clinical relevance, might not achieve similar results. Thirdly, the technique for blood pressure measurement in SPRINT involved the use of an automated device in a quiet room, without staff present, which may not be representative of how blood pressure is measured in busy doctor's practices and this might affect the real world applicability of our results. Fourthly, the SPRINT cohort did not include any diabetics, and further research on blood pressure variability in diabetic patients who may have autonomic nervous system dysfunction will be needed in the future. Lastly, information on medication classes was not made available in this data set, which limited the ability to analyze medication class-related effects on blood pressure variability.
In conclusion, visit-to-visit DBP variability independently predicts cardiovascular outcomes and hypoperfusion-related adverse events in patients with CKD enrolled in SPRINT. More research is needed to define the best and simplest way to evaluate and minimize blood pressure variability in patients with CKD while achieving optimal SBP goals, in clinical practice.
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